Intuitive Surgical, the manufacturer of the Da Vinci surgical robot, announced its Q3 earnings in a call yesterday (19 October) and the market was not happy with the results. The company’s share price dropped by 8% during pre-market trading on the Nasdaq as the company’s $1.74bn revenue fell short of analyst predictions of $1.77bn.
The results were still extremely solid in a vacuum, with a 12% increase in revenue from Q3 2022 and comparable revenues to Q2 of 2023 despite a lower post-tax income. This year-on-year (YoY) revenue growth was led by a 19% growth in Da Vinci procedures. Da Vinci is the world’s most popular surgical robotics suite, used in a range of disciplines to make keyhole surgery simpler and less strenuous for surgeons.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataOne factor that may be key in understanding the share price drop despite the only mild underperformance is the impact of the seemingly unconnected drug Semaglutide. The active ingredient in Wegovy and Ozempic has apparently endless knock-on effects, from altering food brands’ production strategies to reshaping the Danish economy, and the medical device sector is no different.
One of the major uses for Da Vinci is bariatric surgery, which enables weight loss through a range of potential mechanisms. It has long been considered the most effective treatment for long-term weight loss, but the new class of drugs to which Semaglutide belongs are threatening to take that crown.
Intuitive raised the danger of these drugs to its business earlier this year, causing another share rout, though only of 4.5%. Wegovy is available to anyone with a BMI of 30 or over, and it shows no signs of decreasing in popularity, raising questions about longer-term sales of Da Vinci machines.
The company also faces competition from other robotics systems, such as CMR Surgical’s Versius. CMR recently raised $165m in funding, bringing its total valuation to over $1bn. Though the company is less established than Intuitive, it is emerging as a major challenger to the giant.
Surgical robotics remains an area of interest in the Medical Devices field more broadly, with a fairly consistent number of patents filed over the past three years.
Our signals coverage is powered by GlobalData’s Thematic Engine, which tags millions of data items across six alternative datasets — patents, jobs, deals, company filings, social media mentions and news — to themes, sectors and companies. These signals enhance our predictive capabilities, helping us to identify the most disruptive threats across each of the sectors we cover and the companies best placed to succeed.
